- Report
- April 2025
- 50 Pages
Global
From €2412EUR$2,650USD£2,068GBP
- Report
- October 2024
- 183 Pages
Global
From €3226EUR$3,545USD£2,766GBP
€3585EUR$3,939USD£3,073GBP
- Report
- April 2025
- 898 Pages
Global
From €5324EUR$5,850USD£4,564GBP
- Report
- April 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- February 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- March 2025
- 185 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Report
- May 2021
- 177 Pages
United States
€1361EUR$1,495USD£1,166GBP
- Report
- October 2022
- 119 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Report
- February 2023
- 198 Pages
Global
From €6826EUR$7,500USD£5,852GBP
- Report
- April 2025
- 227 Pages
China
From €3640EUR$4,000USD£3,121GBP
- Report
- April 2025
- 114 Pages
China
From €1638EUR$1,800USD£1,404GBP
- Report
- April 2025
- 50 Pages
Global
From €2412EUR$2,650USD£2,068GBP
- Report
- April 2025
- 50 Pages
Global
From €2412EUR$2,650USD£2,068GBP
Zolpidem is a sedative-hypnotic drug used to treat insomnia. It is classified as a Central Nervous System (CNS) drug and is available in both immediate-release and extended-release formulations. Zolpidem works by binding to the GABA-A receptor in the brain, which helps to reduce the time it takes to fall asleep and increases the duration of sleep. Common side effects of zolpidem include dizziness, headache, and nausea.
The zolpidem market is highly competitive, with a number of generic and branded products available. Generic versions of zolpidem are widely available, and many generic manufacturers have entered the market in recent years. Branded products include Ambien, Edluar, and Intermezzo.
Companies in the zolpidem market include Sanofi, Mylan, Teva Pharmaceuticals, Sun Pharmaceuticals, and Apotex. Show Less Read more
